The Company has more than 40 proprietary and partnered product candidates in development
Ablynx participates and presents at IR and scientific conferences
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX.
ABLYNX ANNOUNCES WARRANT EXERCISE20 July 2016
ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB (ALX-0061), AS A MONOTHERAPY IN RA07 July 2016
CORRECTION TRANSPARENCY NOTIFICATION - ADRIANUS VAN HERK ANNOUNCES 3.02% SHAREHOLDING IN ABLYNX16 June 2016
TITAN study - Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura